Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.52 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | PRKACG | P22612 | 1/20 | 0.49 |
| ▸ | PRKACB | P22694 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6274911 | 0.82 | ALDH1A1 (0.47) | ALDH1A1GAAGFERCHEK1 | |
| SCHEMBL14678411 | 0.80 | ALDH1A1 (0.48) | ALDH1A1GAAGFER | |
| SCHEMBL11977139 | 0.79 | GFER (0.47) | ALDH1A1GAAGFERCHEK1 | |
| SCHEMBL23162864 | 0.79 | BAZ2B (0.50) | ALDH1A1GAAGFER | |
| SCHEMBL29521703 | 0.79 | BAZ2B (0.50) | ALDH1A1GAAGFER | |
| SCHEMBL10168733 | 0.78 | PARP11 (0.66) | PARP11PARP10GRM5PARP1PDPK1 | |
| SCHEMBL25947316 | 0.78 | PARP11 (0.66) | PARP11PARP10GRM5PARP1PDPK1 | |
| SCHEMBL30336933 | 0.76 | PRKACA (0.58) | PARP11PARP10PRKACAPRKACGPRKACB | |
| SCHEMBL12683051 | 0.76 | PRKACA (0.58) | PARP11PARP10PRKACAPRKACGPRKACB | |
| SCHEMBL4656012 | 0.75 | PNMT (0.46) | ALDH1A1GAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315881-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| EP-2736330-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013019682-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315881-A1 | COMPOUNDS AND METHODS | RORC, RORB, RORA | PARP11 3019/4885PARP10 2883/4885PRKACA 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.